News

Zacks Investment Research on MSN7h
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Bristol Myers BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy ...
Contract Pharma7h
Bio-Thera & SteinCares Ink Dupilumab Biosimilar Deal for Latin America
Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...
Newseria BIZNES12h
Inflammatory Bowel Disease Market Size to Reach USD 20.08 billion by 2035 - Report by IMARC Group
Inflammatory Bowel Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ​2025-2035​ The report provides a detailed analysis of the current inflammatory ...
Cue Biopharma Gets Positive FDA Feedback on Trial Design
Cue Biopharma has received positive feedback from the Food and Drug Administration for its first in-human trial design for CUE-401, a protein that aims to treat autoimmune disease. The ...
Center for Biosimilars2d
BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability
The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...
Q&A: How parasites—and a bit of serendipity—led to a powerful new drug discovery tool
From cancer to infectious diseases to neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, there ...
C&EN6d
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads - ACS Publications
Inhibition of the S-adenosyl methionine (SAM)-producing metabolic enzyme, methionine adenosyltransferase 2A (MAT2A), has received significant interest in the field of medicinal chemistry due to its ...